We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin (L-Arabinose)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01107431
First Posted: April 21, 2010
Last Update Posted: May 13, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Integrative Health Technologies, Inc.
  Purpose
This study was designed to examine changes in capillary blood glucose and venous insulin levels after a 70 gram oral sucrose challenge with and without simultaneous consumption of a dietary supplement containing L-Arabinose and a patented version of chromium (LA-Cr).

Condition Intervention
Pre-diabetes Dietary Supplement: L-Arabinose and Chromium Dietary Supplement: Sucrose without dietary Supplement

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Combination of L-Arabinose and Chromium Lowers Circulating Glucose and Insulin Levels After Acute Oral Sucrose Challenge

Resource links provided by NLM:


Further study details as provided by Integrative Health Technologies, Inc.:

Primary Outcome Measures:
  • Fasting Blood Glucose [ Time Frame: Every 15 to 30 minutes ]
    Finger-stick glucose measurements taken every 15 or 30 minutes after taking a 70 gram sucrose challenge with and without the dietary supplement


Secondary Outcome Measures:
  • Fasting Blood Insulin Levels [ Time Frame: Every 30 minutes ]
    A venipuncture blood test taken 30, 60, 90 and 120 minutes after taking a 70 gram sucrose challenge with and without taking the dietary supplement


Enrollment: 70
Study Start Date: December 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sucrose with Dietary Supplement
Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
Dietary Supplement: L-Arabinose and Chromium
Consumed 70 grams of sucrose simultaneously taking a dietary supplement
Other Name: 70 grams of cane sugar along with supplement
Active Comparator: Sucrose without Dietary Supplement
Consumed 70 grams of sucrose without simultaneously taking the dietary supplement
Dietary Supplement: Sucrose without dietary Supplement
Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
Other Name: 70 grams of cane sugar with supplement

Detailed Description:
This study concluded that consumption of the LA-Cr supplement in conjunction with a 70-gram sucrose challenge led to a significant reduction of capillary blood glucose and venous insulin as compared to the sucrose challenge without the LA-Cr supplement. This finding may provide an important tool to reduce the adverse effects associated with elevated glucose and insulin levels.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All study subjects were required to contact their family physician to ensure they had no medical conditions that would preclude their participation.

Exclusion Criteria:

  • Diabetics, and
  • Those not approved by their physicians.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01107431


Locations
United States, Texas
Integrative Health Technologies
San Antonio, Texas, United States, 78209
Sponsors and Collaborators
Integrative Health Technologies, Inc.
Investigators
Principal Investigator: Gilbert R Kaats, PhD Integrative Health Technologies
Principal Investigator: Harry G Preuss, MD Georgetown University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gilbert R. Kaats, PhD, Integrative Health Technologies, Inc.
ClinicalTrials.gov Identifier: NCT01107431     History of Changes
Other Study ID Numbers: Pharmachem 40-47
First Submitted: April 19, 2010
First Posted: April 21, 2010
Last Update Posted: May 13, 2011
Last Verified: May 2011

Keywords provided by Integrative Health Technologies, Inc.:
glucose
insulin
L-arabinose
Chromium

Additional relevant MeSH terms:
Chromium
Prediabetic State
Glucose Intolerance
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperglycemia
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Trace Elements
Micronutrients
Growth Substances